Cryo-Cell International Inc.
CCEL evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CCEL—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CCEL
Cryo-Cell International Inc. is a stem cell innovation company focused on umbilical cord blood and cord tissue cellular storage services, with ongoing strategic initiatives in biopharmaceutical manufacturing and clinic operations, while navigating a dispute with Duke University that has paused related investments.
Key risk: Duke dispute halts key investments
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$32.3M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of May 31, 2026.
Cryo-Cell International Inc. is a stem cell innovation company focused on umbilical cord blood and cord tissue cellular storage services, with ongoing strategic initiatives in biopharmaceutical manufacturing and clinic operations, while navigating a dispute with Duke University that has paused related investments.
- Cash & equivalents of $0.5M as of 2026-05-31 [sec].
- Total revenue of $7.8M and net income of $0.6M as of 2026-05-31 [sec].
- Shareholders' equity of -$18.6M and total debt of $8.5M as of 2026-05-31 [sec].
- The company faces a dispute with Duke University (Arbitration Demand) that has paused investments in the Duke License Agreement, including clinical trials and an infusion clinic [sec_mda · as of 2026-07-15].
- Cash flows from operations depend on increasing revenues from cord blood and cord tissue storage services and managing discretionary expenses [sec_mda · as of 2026-07-15].
What works
- The company has a core business in umbilical cord blood and cord tissue cellular storage services, which generates recurring revenue [sec_mda · as of 2026-07-15].
- Cryo-Cell is pursuing global expansion and product diversification, which could open new revenue streams [sec_mda · as of 2026-07-15].
- The company has collaborative research partnerships that may yield future ownership stakes in emerging therapies [sec_mda · as of 2026-07-15].
What to weigh
- The company has negative shareholders' equity of -$18.6M as of 2026-05-31, indicating a structural deficit [sec].
- A dispute with Duke University (Arbitration Demand) has halted investments in the Duke License Agreement, including clinical trials and an infusion clinic, creating uncertainty [sec_mda · as of 2026-07-15].
- Cash flows are dependent on increasing revenues from storage services and managing discretionary expenses, with limited cash reserves of $0.5M [sec] [sec_mda · as of 2026-07-15].
- The company faces risks from consumer discretionary spending selectivity and competitive pressure from public cord blood banking [sec_mda · as of 2026-07-15].
From the filings
Quoted directly from source documents.
The Duke dispute has paused investments in the Duke License Agreement.
“Until the Duke dispute is resolved, the Company does not anticipate making further investments in activities related to the Duke License Agreement.”
SEC MD&A · July 15, 2026
Cash flows depend on increasing revenues from storage services.
“cash flows from operations will depend primarily upon increasing revenues from sales of its umbilical cord blood and cord tissue cellular storage services and managing discretionary expenses.”
SEC MD&A · July 15, 2026
Risks & what to watch (4)›
Key risks
- Duke dispute halts key investments — Arbitration Demand against Duke University has paused investments in clinical trials and infusion clinic, creating uncertainty [sec_mda · as of 2026-07-15].
- Negative shareholders' equity — Shareholders' equity of -$18.6M as of 2026-05-31 indicates a structural deficit [sec].
- Low cash reserves — Cash & equivalents of only $0.5M as of 2026-05-31, limiting financial flexibility [sec].
- Dependence on revenue growth — Cash flows depend on increasing storage service revenues and managing discretionary expenses [sec_mda · as of 2026-07-15].
What to watch
- Resolution of the Duke Arbitration Demand and its impact on the Duke License Agreement investments [sec_mda · as of 2026-07-15].
- Trends in revenue from umbilical cord blood and cord tissue storage services [sec_mda · as of 2026-07-15].
- Cash position and ability to fund operations without additional capital [sec].
- Progress in global expansion and product diversification initiatives [sec_mda · as of 2026-07-15].
Sources: SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run Cryo-Cell International Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Cryo-Cell International Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
Profitable (positive operating cash flow)
OCF $2M · Net income $555K · Debt/OCF 1.1×
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
8
Total value held
$1.5M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 323,048 | $1.1M |
| geode capital management, llc | 43,616 | $155K |
| vanguard fiduciary trust co | 23,346 | $83K |
| blackrock, inc. | 13,983 | $50K |
| susquehanna international group, llp | 10,018 | $36K |
| osaic holdings, inc. | 2,500 | $9K |
| morgan stanley | 601 | $2K |
| signaturefd, llc | 100 | $355 |
Short Interest
as of May 20, 2026- % of float
- 0.1%
- Days to cover
- 0.7
- Shares short
- 7,016
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CCEL short interestGovernance
Frequently asked questions
What is the AI investment thesis for Cryo-Cell International Inc.?
Cryo-Cell International Inc. is a stem cell innovation company focused on umbilical cord blood and cord tissue cellular storage services, with ongoing strategic initiatives in biopharmaceutical manufacturing and clinic operations, while navigating a dispute with Duke University that has paused related investments.
Who is the CEO of Cryo-Cell International Inc.?
Mr. David I. Portnoy is the chief executive officer of Cryo-Cell International Inc. (CCEL).
Where is Cryo-Cell International Inc. headquartered?
Cryo-Cell International Inc. (CCEL) is headquartered in Oldsmar, FL, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.